UCB SA (UCB.BR) Stock Fundamental Analysis

EBR:UCB • BE0003739530

248.4 EUR
-21.3 (-7.9%)
Last: Feb 26, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

Taking everything into account, UCB scores 6 out of 10 in our fundamental rating. UCB was compared to 52 industry peers in the Pharmaceuticals industry. UCB is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. UCB is growing strongly while it is still valued neutral. This is a good combination! These ratings could make UCB a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year UCB was profitable.
  • UCB had a positive operating cash flow in the past year.
  • Each year in the past 5 years UCB has been profitable.
  • UCB had a positive operating cash flow in each of the past 5 years.
UCB.BR Yearly Net Income VS EBIT VS OCF VS FCFUCB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

1.2 Ratios

  • The Return On Assets of UCB (7.75%) is comparable to the rest of the industry.
  • UCB has a Return On Equity (13.76%) which is comparable to the rest of the industry.
  • UCB's Return On Invested Capital of 11.63% is in line compared to the rest of the industry. UCB outperforms 59.62% of its industry peers.
  • UCB had an Average Return On Invested Capital over the past 3 years of 4.35%. This is significantly below the industry average of 14.12%.
  • The last Return On Invested Capital (11.63%) for UCB is above the 3 year average (4.35%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.75%
ROE 13.76%
ROIC 11.63%
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
UCB.BR Yearly ROA, ROE, ROICUCB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8 10

1.3 Margins

  • UCB has a Profit Margin of 19.45%. This is in the better half of the industry: UCB outperforms 75.00% of its industry peers.
  • In the last couple of years the Profit Margin of UCB has remained more or less at the same level.
  • UCB has a Operating Margin of 26.58%. This is in the better half of the industry: UCB outperforms 67.31% of its industry peers.
  • In the last couple of years the Operating Margin of UCB has declined.
  • Looking at the Gross Margin, with a value of 73.38%, UCB is in the better half of the industry, outperforming 65.38% of the companies in the same industry.
  • UCB's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 26.58%
PM (TTM) 19.45%
GM 73.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
UCB.BR Yearly Profit, Operating, Gross MarginsUCB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • UCB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, UCB has about the same amount of shares outstanding.
  • The number of shares outstanding for UCB has been increased compared to 5 years ago.
  • The debt/assets ratio for UCB has been reduced compared to a year ago.
UCB.BR Yearly Shares OutstandingUCB.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
UCB.BR Yearly Total Debt VS Total AssetsUCB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • UCB has an Altman-Z score of 5.64. This indicates that UCB is financially healthy and has little risk of bankruptcy at the moment.
  • UCB has a better Altman-Z score (5.64) than 80.77% of its industry peers.
  • UCB has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as UCB would need 2.43 years to pay back of all of its debts.
  • The Debt to FCF ratio of UCB (2.43) is better than 82.69% of its industry peers.
  • A Debt/Equity ratio of 0.29 indicates that UCB is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.29, UCB is doing good in the industry, outperforming 69.23% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 2.43
Altman-Z 5.64
ROIC/WACC1.46
WACC7.96%
UCB.BR Yearly LT Debt VS Equity VS FCFUCB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 1.35 indicates that UCB should not have too much problems paying its short term obligations.
  • The Current ratio of UCB (1.35) is comparable to the rest of the industry.
  • UCB has a Quick Ratio of 1.01. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.01, UCB is in line with its industry, outperforming 53.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.01
UCB.BR Yearly Current Assets VS Current LiabilitesUCB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • UCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.41%, which is quite impressive.
  • Measured over the past years, UCB shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.86% on average per year.
  • The Revenue has grown by 25.56% in the past year. This is a very strong growth!
  • Measured over the past years, UCB shows a small growth in Revenue. The Revenue has been growing by 4.60% on average per year.
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%

3.2 Future

  • Based on estimates for the next years, UCB will show a very strong growth in Earnings Per Share. The EPS will grow by 30.00% on average per year.
  • Based on estimates for the next years, UCB will show a quite strong growth in Revenue. The Revenue will grow by 15.34% on average per year.
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y30%
Revenue Next Year28.22%
Revenue Next 2Y20.45%
Revenue Next 3Y17.95%
Revenue Next 5Y15.34%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
UCB.BR Yearly Revenue VS EstimatesUCB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B
UCB.BR Yearly EPS VS EstimatesUCB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20 25

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 38.69, UCB can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, UCB is valued a bit more expensive than 61.54% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of UCB to the average of the S&P500 Index (27.21), we can say UCB is valued slightly more expensively.
  • With a Price/Forward Earnings ratio of 24.15, UCB is valued on the expensive side.
  • UCB's Price/Forward Earnings ratio is in line with the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.13, UCB is valued at the same level.
Industry RankSector Rank
PE 38.69
Fwd PE 24.15
UCB.BR Price Earnings VS Forward Price EarningsUCB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 61.54% of the companies in the same industry are cheaper than UCB, based on the Enterprise Value to EBITDA ratio.
  • UCB's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 40.77
EV/EBITDA 21.55
UCB.BR Per share dataUCB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • UCB has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as UCB's earnings are expected to grow with 38.91% in the coming years.
PEG (NY)0.64
PEG (5Y)N/A
EPS Next 2Y43.7%
EPS Next 3Y38.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • UCB has a yearly dividend return of 0.34%, which is pretty low.
  • Compared to an average industry Dividend Yield of 1.89, UCB is paying slightly less dividend.
  • With a Dividend Yield of 0.34, UCB pays less dividend than the S&P500 average, which is at 1.80.
Industry RankSector Rank
Dividend Yield 0.34%

5.2 History

  • The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years6
Div Non Decr Years6
UCB.BR Yearly Dividends per shareUCB.BR Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • 19.82% of the earnings are spent on dividend by UCB. This is a low number and sustainable payout ratio.
  • UCB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP19.82%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
UCB.BR Yearly Income VS Free CF VS DividendUCB.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
UCB.BR Dividend Payout.UCB.BR Dividend Payout, showing the Payout Ratio.UCB.BR Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

UCB SA

EBR:UCB (2/26/2026, 7:00:00 PM)

248.4

-21.3 (-7.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)02-26
Inst Owners41.62%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap48.32B
Revenue(TTM)6.85B
Net Income(TTM)1.33B
Analysts73.85
Price Target275.68 (10.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.34%
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP19.82%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.49%
PT rev (3m)6.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)3.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.27%
Revenue NY rev (3m)4.16%
Valuation
Industry RankSector Rank
PE 38.69
Fwd PE 24.15
P/S 7.06
P/FCF 40.77
P/OCF 30.66
P/B 4.99
P/tB 44.45
EV/EBITDA 21.55
EPS(TTM)6.42
EY2.58%
EPS(NY)10.28
Fwd EY4.14%
FCF(TTM)6.09
FCFY2.45%
OCF(TTM)8.1
OCFY3.26%
SpS35.21
BVpS49.78
TBVpS5.59
PEG (NY)0.64
PEG (5Y)N/A
Graham Number84.8
Profitability
Industry RankSector Rank
ROA 7.75%
ROE 13.76%
ROCE 13.73%
ROIC 11.63%
ROICexc 13.71%
ROICexgc 58.2%
OM 26.58%
PM (TTM) 19.45%
GM 73.38%
FCFM 17.3%
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexgc growth 3Y-25.87%
ROICexgc growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 2.43
Debt/EBITDA 1.15
Cap/Depr 61.48%
Cap/Sales 5.71%
Interest Coverage 16.4
Cash Conversion 64.17%
Profit Quality 88.96%
Current Ratio 1.35
Quick Ratio 1.01
Altman-Z 5.64
F-Score9
WACC7.96%
ROIC/WACC1.46
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y30%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
Revenue Next Year28.22%
Revenue Next 2Y20.45%
Revenue Next 3Y17.95%
Revenue Next 5Y15.34%
EBIT growth 1Y258.97%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year162.81%
EBIT Next 3Y59.8%
EBIT Next 5Y41.09%
FCF growth 1Y91.13%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y61.64%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%

UCB SA / UCB.BR FAQ

What is the fundamental rating for UCB stock?

ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR.


Can you provide the valuation status for UCB SA?

ChartMill assigns a valuation rating of 4 / 10 to UCB SA (UCB.BR). This can be considered as Fairly Valued.


Can you provide the profitability details for UCB SA?

UCB SA (UCB.BR) has a profitability rating of 6 / 10.


What are the PE and PB ratios of UCB SA (UCB.BR) stock?

The Price/Earnings (PE) ratio for UCB SA (UCB.BR) is 38.69 and the Price/Book (PB) ratio is 4.99.


What is the earnings growth outlook for UCB SA?

The Earnings per Share (EPS) of UCB SA (UCB.BR) is expected to grow by 60.25% in the next year.